Patients with compromised immune function suffer a wide variety of lung insults. Infections are the most common causes of both acute and chronic lung diseases, but many noninfectious conditions affect the lungs. The clinical presentation of these noninfectious conditions often mimic infections, thus causing diagnostic dilemmas. The spectrum of noninfectious lung injury and response in the immunosuppressed host includes interstitial edema, interstitial fibrosis, diffuse idiopathic pneumonia, acute respiratory distress syndrome, and obliterative bronchiolitis. Alveolar hemorrhage may complicate any of these conditions. Lung injury in the immunosuppressed host is associated with a diversity of etiologies: sepsis, irradiation, graft rejection, reperfusion injury, graft-versus-host disease, and chemotherapeutic agents and other drug reactions. These injuries most often present as diffuse pulmonary infiltrates on chest radiograph. Establishing a specific diagnosis and etiology for the injury is often problematic. From a pragmatic standpoint, excluding the possibility of infection is the principal aim of diagnostic testing.

1.
Grossman J, Kahn F: Noninfectious pulmonary disease in the immunocompromised host. Semin Respir Med 1989;10:78–88.
2.
Ognibene FP, Martin SE, Parker MM, Schlesinger T, Roach P, Burch C, Shelhamer JH, Parrillo JE: Adult respiratory distress syndrome in patients with severe neutropenia. N Engl J Med 1986;315:547–551.
3.
Tenholder MF, Hooper RG: Pulmonary infiltrates in leukemia. Chest 1980;78:468–473.
4.
Mah K, van Dyk J, Reane T, et al: Acute radiation-induced pulmonary damage: A clinical study on the response to fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1987;13:179.
5.
Morgan GW, Pharm B, Breit SN: Radiation and the lung: A reevaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys 1995;31:361.
6.
Sloane JP, Depledge MH, Powles RL, Morgenstern GR, Trickey BS, Dady PJ: Histopathology of the lung after bone marrow transplantation. J Clin Pathol 1983;36:546–554.
7.
McDonald S, Rubin P, Phillips TL, et al: Injury to the lung from cancer therapy: Clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995;31:1187.
8.
Nambu Y, Ohya N: Radiation pneumonia; in Basic and Clinical Aspects of Pulmonary Fibrosis. Boca Raton, CRC Press, 1994, p 445.
9.
Rosiello RA, Merrill WM: Radiation-induced lung injury. Clin Chest Med 1990;11:65.
10.
Rubin P, Casseratt GW (eds): Respiratory System. Clinical Radiation Pathology. Philadelphia, Saunders, 1968, vol 1, p 423.
11.
Ikezoe J, Takashima S, Morimoto S, et al: CT appearance of acute radiation-induced injury in the lung. Am J Roentgenol 1988;150:765.
12.
Pickrell JA, Abdel-Mageed AB: Radiation-induced pulmonary fibrosis; in Lung Biology in Health and Disease: Pulmonary Fibrosis. New York, Dekker, 1995, p 363.
13.
Cooper JAD, White DA, Matthay RA: Drug induced pulmonary disease. 1. Cytotoxic drugs. Am Rev Respir Dis 1986;133:321.
14.
White DA, Schwartzberg LS, Kris MG, et al: Acute chest pain during bleomycin infusions. Cancer 1987;59:1582–1585.
15.
Yousem SA, Lifson JD, Colby TV: Chemotherapy-induced eosinophilic pneumonia. Chest 1985;88:103–106.
16.
Kris MG, Pablo D, Graller J, et al: Dyspnea following vinblastine or vedesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy. Cancer Treat Rep 1984;68:1029–1031.
17.
Sheldon R, Slaughter D: A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 1986;58:1428–1436.
18.
Podoll LN, Winkler SS: Busulfan lung: Report of two cases and report of the literature. Am J Roentgenol 1974;120:151.
19.
Hankins DG, Sanders S, MacDonald FM, Drage CW: Pulmonary toxicity recurring after a six week course of busulfan therapy and after subsequent therapy with uracil mustard. Chest 1978;73:415.
20.
Lane SD, Besa EC, Justh G, et al: Fatal interstitial pneumonitis following high-dose intermittent chlorambucil therapy for chronic lymphocytic leukemia. Cancer 1981;47:32.
21.
Grand JI, Spector H, Zimbler JS: Pulse dose chlorambucil-induced interstitial pneumonitis. Proc Am Soc Clin Oncol 1983;2:22.
22.
Crestani B, Jaccard A, Isa’l-Biet D, et al: Chlorambucil-associated pneumonitis. Chest 1994;105:634.
23.
Cronstein BN: Methotrexate and its mechanism of action. Arthritis Rheum 1996;39:1951.
24.
Lynch JP III, McCune J: Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997;155:395.
25.
Hassell A, Dawes P: Serious problems with methotrexate. Br J Rheumatol 1994;33:1001.
26.
Carroll GR, Graeme J, Thomas R, et al: Incidence, prevalence, and possible risk factors for pneumonitis with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994;21:51.
27.
Rosenow EC III: Drug induced pulmonary disease. Dis Mon 1994;40:253.
28.
White D, Gupta S, Rankin JA, et al: Methotrexate pneumonitis: Bronchoalveolar lavage fluid findings suggest an immunologic disorder. Am Rev Respir Dis 1989;139:18.
29.
Schnabel A, Richter C, Bauerfeind S, Gross WL: Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis. Thorax 1997;52:377.
30.
Bedrosian CWM: Iatrogenic and toxic injury; in Dail DH, Hammar SP (eds): New York, Springer, 1988, pp 511–534.
31.
Weiss RB, Poster DS, Penta JS: The nitrosureas and pulmonary toxicity. Cancer Treat Rev 1981;8:11–125.
32.
Selker RG, Jacobs SA, Moore PB, et al: 1,3-Bis(2-chloroethyl)-1-nitrosurea (BCNU)-induced pulmonary fibrosis. Neurosurgery 1980;7:560.
33.
Durant JR, Norgard MJ, Murad TM, et al: Pulmonary toxicity associated with bis-chloroethylnitrosurea (BCNU). Ann Intern Med 1979;90:191.
34.
Schmitz N, Diehl V: Carmustine and the lungs (correspondence). Lancet 1997;349:1712–1713.
35.
O’Driscoll BR, Hasleton PS, Taylor PM, et al: Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990;323:378.
36.
Donehower RC, Rowinsky EK: An overview of the experience with Taxol (paclitaxel) in the USA. Cancer Treat Rev 1993;19(suppl):63.
37.
Horwitz SB: Mechanism of action of taxol. Trends Pharmacol Sci 1992;13:134.
38.
Sarosy G, Reed E: Taxol dose intentification and its clinical implications. J Natl Med Assoc 1993;85:427.
39.
Stemmer SM, Cagnoni PJ, Shpall EJ, et al: High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: A phase I trial. J Clin Oncol 1996;14:1463–1472.
40.
Ramanathan RK, Belani CP: Transient pulmonary infiltrates: A hypersensitivity reaction to paclitaxel. Ann Intern Med 1996;124:278.
41.
Rowinsky EK, Donehower RC: Paclitaxel (taxol). N Engl J Med 1995;332:1004.
42.
Weiss RB, Donehower RC, Wiernik PH, et al: Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263.
43.
Essayan DM, Kagey-Sobotka A, Lichtenstein LM, et al: Paclitaxel hypersensitivity revisited. J Clin Oncol 1996;14:1042.
44.
Essayan DM, Kagey-Sobotka A, Colarusso PJ, et al: Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 1996;97:42.
45.
Wingard JR, Mellits ED, Sostrin MB, Chen DY-H, Burns WH, Santos GW, Vriesendorp HM, Beschorner WE, Saral R: Interstitial pneumonia after allogeneic marrow transplantation. Medicine (Baltimore) 1988;67:175–186.
46.
Atkinson K, Nivison-Smith I, Dodds A, Concannon A, Milliken S, Downs K: A comparison of the pattern of interstitial pneumonia following allogeneic bone marrow transplantation before and after the introduction of prophylactic ganciclovir therapy in 1989. Bone Marrow Transplant 1998;21:691–697.
47.
Clark JG, Hansen JA, Hertz MI, Parkman R, Jensen L, Peavy H: NHLBI Workshop Summary: Idiopathic pneumonia syndrome following bone marrow transplantation. Am Rev Respir Dis 1992;147:1601–1606.
48.
Robbins RA, Linder J, Stahl MG, Thompson AB, Haire W, Kessinger A, Armitage JO, Arneson M, Woods G, Vaughn WP, Rennard SI: Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 1989;87:511–518.
49.
Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW: Idiopathic pneumonia syndrome: The changing spectrum of lung injury after marrow transplantation. Transplantation 1997;63:1079–1086.
50.
Palmas A, Tefferi A, Myers JL, Scott JP, Swensen SJ, Chen MG, Gastineau DA, Gertz MA, Inward DJ, Lacy MQ, Litzow MR: Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation. Br J Haematol 1998;100:680–687.
51.
Todd NW, Peters WP, Ost AH, Roggli VL, Piantadosi CA: Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis 1993;147:1264–1270.
52.
Tenholder MF, Hooper RG: Pulmonary hemorrhage in the immunocompromised host: An elusive reality. Am Rev Respir Dis 1980;121(suppl):198.
53.
Agusti C, Ramirez J, Picado C, Xaubet A, Carreras E, Ballester E, Torres A, Battochia C, Rodriquez-Roisin R: Diffuse alveolar hemorrhage in allogeneic bone marrow transplantation: A post-mortem study. Am J Respir Crit Care Med 1995;151:1006–1010.
54.
DeLassence A, Fleury-Feith J, Escudier E, Beaune J, Bernaudin J-E, Cordonnier C: Alveolar hemorrhage: Diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med 1995;151:151–163.
55.
Trulock EP: Lung transplantation. Am J Respir Crit Care Med 1997;155:789–818.
56.
Yousem SA, Duncan SR, Griffith BP: Interstitial and airspace granulation tissue reactions in lung transplant recipients. Am J Surg Pathol 1992;16:877–884.
57.
Date H, Triantafillou AN, Trulock EP, Pohl MS, Cooper JD, Patterson GA: Inhaled nitric oxide reduced human allograft dysfunction. J Thorac Cardiovasc Surg 1996;111:913–919.
58.
Bradley JA, Bolton EM: The T-cell requirements for allograft rejection. Transpl Rev 1992;6:115–129.
59.
Boehler A, Kesten S, Weder W, Speich R: Bronchiolitis obliterans after lung transplantation: A review. Chest 1998;114:1411–1426.
60.
International Society for Heart and Lung Transplantation, Cooper JD, Billingham M, Egan T, Hertz MI, Higenbottom T, Lynch J, Maurer J, Paradis I, Patterson GA, Smith C, Trulock EP, Vreim C, Yousem S: A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. J Heart Lung Transplant 1993;12:713–719.
61.
Date H, Lynch JP, Sundaresan S, Patterson GA, Trulock EP: The impact of cytolytic therapy on bronchiolitis obliterans syndrome. J Heart Lung Transpl 1998;17:869–875.
62.
Valentine VG, Robbins RC, Berry GJ, Patel HR, Reichenspurner H, Reitz BA, Theodore J: Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant 1996;15:371–383.
63.
Chan CK, Hyland RH, Hutcheon MA, et al: Small-airways disease in recipients of allogeneic bone marrow transplants. An analysis of 11 cases and a review of the literature. Medicine 1987;66:327–340.
64.
Clark JG, Schwartz DA, Flournoy N, Sullivan KM, Crawford SW, Thomas ED: Risk factors for airflow obstruction in recipients of bone marrow transplants. Ann Intern Med 1987;107:648–656.
65.
Paz HL, Crilley P, Patchefsky A, Schiffman RL, Brodsky I: Bronchiolitis obliterans after autologous bone marrow transplantation. Chest 1992;101:775–778.
66.
St. John RC, Gadek JE, Tutschka P, Kapoor N, Dorinsky PM: Analysis of airflow obstruction by bronchoalveolar lavage following bone marrow transplantation: Implications for pathogenesis and treatment. Chest 1990;98:600–607.
67.
Crawford SW, Clark JG: Bronchiolitis associated with bone marrow transplantation. Clin Chest Med 1993;14:741–749.
68.
McKee LC Jr, Collins RD: Intravascular leukocyte thrombi and aggregates as a cause of morbidity and mortality in leukemia. Medicine 1974;53:463–478.
69.
Wardman AG, Milligan DW, Child JA, Delamore IW, Cooke NJ: Pulmonary infiltrates and adult acute leukaemia: Empirical treatment and survival related to the extent of pulmonary radiological disease. Thorax 1984;39:568–571.
70.
Vernant JP, Brun B, Mannoni P, Dreyfus B: Respiratory distress of hyperleukocytic granulocytic leukemias. Cancer 1979;44:264–268.
71.
Ross JS, Ellman L: Leukemic infiltration of the lungs in the chemotherapeutic era. Am J Clin Pathol 1974;61:235–241.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.